Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor

BMJ Case Rep. 2017 Jan 10:2017:bcr2016216331. doi: 10.1136/bcr-2016-216331.

Abstract

A 46-year-old woman with a history of dasatinib-resistant chronic myeloid leukaemia, clonal evolution and monosomy 7 underwent reduced intensity conditioned in vivo T-cell-depleted allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor. Following the transplantation, she developed recurrent cutaneous graft versus host disease (GvHD), which required treatment with systemic immunosuppression and electrocorporeal photophoresis. Concurrently, she developed a lichenoid rash with granulomatous features suggestive of cutaneous sarcoidosis. Additional treatment with hydroxychloroquine was initially successful, but 2 months later, she developed erythroderma with palpable lymphadenopathy. Repeated histological analysis established a diagnosis of folliculotropic mycosis fungoides stage IVA2, and the malignant clone was confirmed to be of donor origin. A positive response to brentuximab has been shown. This is the first reported case of primary mycosis fungoides after matched unrelated donor HSCT, and in a patient still undergoing treatment for GvHD.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Female
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Mycosis Fungoides / drug therapy
  • Mycosis Fungoides / etiology*
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / etiology*
  • Transplantation Chimera
  • Transplantation, Homologous / adverse effects
  • Treatment Outcome
  • Unrelated Donors